-+ 0.00%
-+ 0.00%
-+ 0.00%

Equillium wins Australian regulatory clearance for EQ504 Phase 1 trial

PUBT·10/05/2026 20:06:13
Listen to the news
Equillium wins Australian regulatory clearance for EQ504 Phase 1 trial
  • Equillium secured Australian TGA clearance under the CTN scheme to start a first-in-human Phase 1 trial of EQ504.
  • HREC approval received. First dosing expected by early November 2026. Topline Phase 1 data projected about six months later.
  • Program supports a potential ulcerative colitis proof-of-concept study in the second half of 2027, pending Phase 1 results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051605PRIMZONEFULLFEED9839913) on October 05, 2026, and is solely responsible for the information contained therein.